← Leaderboards
Jeffrey Samuel Hyams
Connecticut Children'S Medical Center
$10,482,484
Attributed
$24,064,691
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,064,691 · 5
By mechanism
U01$18,834,997 · 2
R01$4,332,293 · 1
U34$897,401 · 2
Top collaborators
- Lee Armistead Denson18 shared
- Subra Kugathasan4 shared
- Mi-Ok Kim2 shared
Most similar at Connecticut Children'S Medical Center
Same institution · by research overlap
- Lee Armistead Denson$26,253,281
- Subra Kugathasan$21,188,663
Others in their field
Top investigators on “S Disease”
- Lawrence Corey · Fred Hutchinson Cancer Center$643,566,627
- Jeffrey P Krischer · University Of South Florida$588,279,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$477,614,997
- David Heimbrook · Leidos Biomedical Research, Inc.$470,438,912
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$389,132,404
Research focus
S DiseaseDisease RemissionPharmaceutical PreparationsChildCrohn&AposChildhoodClinical RemissionResponseFutureDiagnosisClinical PracticeAdultIndexingHealingChronicInflammatory Bowel DiseasesDoseGenesPathogenesisInflammationAnti-Tumor Necrosis Factor TherapyCohort StudiesColonGenetic Signature
Grant awards (18)
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed with Crohn's Disease$2,900,000
U01 · FY2025 · DK · contact PI
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$677,278
R01 · FY2025 · HD
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed with Crohn's Disease$2,701,767
U01 · FY2024 · DK · contact PI
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$710,020
R01 · FY2024 · HD
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed with Crohn's Disease$2,799,999
U01 · FY2023 · DK · contact PI
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$467,323
R01 · FY2022 · HD
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$658,089
R01 · FY2021 · HD
Clinical, imaging, and endoscopic outcomes of children newly diagnosed with Crohn's disease$391,223
U34 · FY2021 · DK · contact PI
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$666,974
R01 · FY2020 · HD
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$667,198
R01 · FY2019 · HD
Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease$485,411
R01 · FY2018 · HD
Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study$1,332,762
U01 · FY2016 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study$1,581,943
U01 · FY2015 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study$2,311,223
U01 · FY2014 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study$2,522,332
U01 · FY2013 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study$2,684,971
U01 · FY2012 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study$81,643
U34 · FY2011 · DK · contact PI
Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study$424,535
U34 · FY2010 · DK · contact PI